Quizartinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Quizartinib. Educational only — not medical advice.
Labeled uses
VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1) and Clinical Studies (14) ] .
Source: FDA labeling via NIH DailyMed (set 29cdbcfe…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.